Arkansas Financial Group Inc. Has $444,000 Position in Johnson & Johnson (NYSE:JNJ)

Arkansas Financial Group Inc. boosted its stake in Johnson & Johnson (NYSE:JNJ) by 18.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,682 shares of the company’s stock after purchasing an additional 424 shares during the quarter. Arkansas Financial Group Inc.’s holdings in Johnson & Johnson were worth $444,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the company. Moneta Group Investment Advisors LLC increased its position in Johnson & Johnson by 90,144.4% in the 4th quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after acquiring an additional 54,326,454 shares during the period. Norges Bank bought a new stake in Johnson & Johnson in the fourth quarter valued at $4,609,399,000. Providence Capital Advisors LLC increased its holdings in shares of Johnson & Johnson by 141,974.0% during the first quarter. Providence Capital Advisors LLC now owns 4,750,956 shares of the company’s stock valued at $30,651,000 after acquiring an additional 4,747,612 shares in the last quarter. Morgan Stanley grew its holdings in shares of Johnson & Johnson by 12.0% during the fourth quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock valued at $7,458,962,000 after buying an additional 4,521,062 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its stake in shares of Johnson & Johnson by 15.1% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 29,277,774 shares of the company’s stock worth $5,171,919,000 after purchasing an additional 3,849,148 shares during the last quarter. 68.40% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have commented on JNJ. Credit Suisse Group lifted their target price on shares of Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a research report on Friday, July 21st. Stifel Nicolaus boosted their price target on shares of Johnson & Johnson from $165.00 to $175.00 in a report on Friday, July 21st. TheStreet upgraded shares of Johnson & Johnson from a “c+” rating to a “b+” rating in a research note on Monday, August 21st. Morgan Stanley lowered their price target on shares of Johnson & Johnson from $187.00 to $172.00 and set an “equal weight” rating on the stock in a report on Thursday, August 31st. Finally, Wells Fargo & Company decreased their target price on Johnson & Johnson from $195.00 to $186.00 and set an “overweight” rating for the company in a research report on Thursday, August 31st. Nine equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $170.65.

Johnson & Johnson Trading Up 0.6 %

NYSE:JNJ opened at $162.41 on Tuesday. The company has a market cap of $422.10 billion, a PE ratio of 32.88, a price-to-earnings-growth ratio of 3.26 and a beta of 0.54. The company has a current ratio of 1.12, a quick ratio of 0.88 and a debt-to-equity ratio of 0.44. The company has a 50 day simple moving average of $166.21 and a two-hundred day simple moving average of $161.83. Johnson & Johnson has a 12 month low of $150.11 and a 12 month high of $181.04.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. The company had revenue of $25.53 billion during the quarter, compared to analysts’ expectations of $24.63 billion. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. Johnson & Johnson’s revenue for the quarter was up 6.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.59 earnings per share. Research analysts forecast that Johnson & Johnson will post 10.03 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 7th. Stockholders of record on Monday, August 28th were given a dividend of $1.19 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.93%. Johnson & Johnson’s payout ratio is 96.36%.

Insider Activity at Johnson & Johnson

In related news, insider William Hait sold 14,698 shares of Johnson & Johnson stock in a transaction dated Wednesday, July 26th. The shares were sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the completion of the transaction, the insider now directly owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other Johnson & Johnson news, VP Peter Fasolo sold 20,000 shares of the stock in a transaction dated Tuesday, July 25th. The shares were sold at an average price of $170.32, for a total transaction of $3,406,400.00. Following the completion of the sale, the vice president now directly owns 102,696 shares of the company’s stock, valued at $17,491,182.72. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider William Hait sold 14,698 shares of the company’s stock in a transaction on Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total value of $2,528,056.00. Following the transaction, the insider now directly owns 87,747 shares in the company, valued at $15,092,484. The disclosure for this sale can be found here. 0.20% of the stock is currently owned by insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.